BIOGUARD Wound Dressings with NIMBUS Technology May Provide Safeguards Against Influenza Viruses

    GAINESVILLE, FL, December 18, 2009 /24-7PressRelease/ -- Quick-Med Technologies, Inc. (OTCBB: QMDT) announced today that its licensee, Derma Sciences, Inc. (OTCBB: DSCI), has reported that an independent laboratory has found that BIOGUARD barrier gauze dressings with Quick-Med's novel NIMBUS antimicrobial technology exhibit high antiviral efficacy against the H1N1 virus. This new information increases the applicability of the dressings, which have already been shown to have high efficacy against virulent bacteria such as MRSA.

BCS Laboratories Inc. of Gainesville, Florida exposed two varieties of BIOGUARD dressings to quantities of the Influenza A (H1N1; ATCC VR-1469) virus for a period of 24 hours. At the end of this interval, quantities of the virus were found to be reduced in both dressing types by an average percentage of 99.93%.

Although human-to-human transmission of H1N1 virus can occur through coughing or sneezing by people infected with the influenza virus, or by touching something with flu viruses on it and then touching one's mouth or nose, the potential also exists of transmission via cross-contamination during wound dressing changes. This is especially true if the dressing is soaked with wound fluid, which can increase the time the virus survives in the dressing. When an infected wound's dressing is changed, pathogens within the dressing are potentially made airborne, increasing the risk of infection to those in the immediate vicinity. Wound care patients also run the risk of being infected by a virus as their dressings are changed. The H1N1 virus can be easily transmitted from the wound dressings to the hands of healthcare workers, while small airborne droplets of wound fluid with H1N1 can be inhaled by doctors, nurses or patients.

The Centers for Disease Control and Prevention (CDC) reported last week that swine flu has caused nearly 10,000 deaths in the United States as of mid-November, part of an outbreak that has already infected about 50 million Americans.

About BIOGUARD Wound Dressings
BIOGUARD dressings, which were introduced in June by Derma Sciences, are the first wound care products to feature Quick-Med's novel, FDA-cleared NIMBUS technology. The dressings serve as a barrier to infection, kill germs absorbed into the dressing, and do not interfere with tissue healing. The NIMBUS active agent maintains effectiveness even in the presence of large amounts of proteinaceous exudates.

NIMBUS is unique in that it is the only non-leaching antimicrobial wound dressing, which the Company believes is an important distinction; other antimicrobial dressings rely on the release of chemicals to the wound bed that can impede the wound healing process. By its design, NIMBUS poses minimal risk of bacteria developing resistance.

Quick-Med's NIMBUS barrier gauze wound dressing received market clearance in February from the U.S. Food and Drug Administration via FDA's De Novo review process, a special clearance program for low-risk medical devices that are found to be "not substantially equivalent" to any predicate device. Derma Sciences reported first commercial sales in late June. NIMBUS technology is protected by nine Quick-Med U.S. patents and patents pending and 24 foreign counterparts.

About Quick-Med Technologies, Inc.

Quick-Med Technologies, Inc. is a life sciences company that is developing innovative technologies for the healthcare and consumer markets. Quick-Med is developing NIMBUS and NimbuDerm applications in several advanced medical device formats including traditional and advanced wound care dressings, adhesives, medical grade thermoplastics, and skin sanitizers. NIMBUS is the FDA-cleared technology that is being marketed in a line of wound dressings. The company has also recently announced its Stay Fresh technology for apparel and other textile applications. For more information, see: www.quickmedtech.com.

CONTACT:
J. Ladd Greeno, CEO
Tel. (888) 835.2211 Ext 102
Email: [email protected]

2009 Quick-Med Technologies, Inc. All rights reserved. NIMBUS is a registered trademark of Quick-Med Technologies, Inc. BIOGUARD is a trademark of Derma Sciences, Inc.

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "expect", "plan", "believe", "anticipate", "intend", "could", "would", "estimate", and/or "continue" or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements involve risks and uncertainties, including those risks that are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"), which may be accessed at the SEC's Edgar System at www.sec.gov.

# # #